Know Cancer

forgot password

A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1
18 Years
Open (Enrolling)

Thank you

Trial Information

A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)



- To establish the maximum-tolerated dose (MTD) of everolimus in combination with R-CHOP
(rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and
prednisone) chemotherapy.

- To assess the feasibility of everolimus in combination with standard R-CHOP
chemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma.


- To describe the toxicities associated with everolimus in combination with R-CHOP

- To further describe the toxicities associated with everolimus in combination with
R-CHOP chemotherapy.

- To assess the rate of event-free survival (EFS) at 12 months for diffuse large B-cell
lymphoma patients treated with everolimus in combination with R-CHOP chemotherapy.

- To evaluate overall response rate, complete response rate, duration of response, EFS,
overall survival, and progression-free survival for patients treated with everolimus in
combination with R-CHOP chemotherapy.


- To profile gene expression using immunohistochemistry and categorize patients as
germinal-center B-cell-like (GBC) vs activated B-cell-like (ABC) vs unclassified
lymphoma subtype. (exploratory)

- To determine whether previously identified predictive markers in large cell lymphoma
remain valid with the addition of everolimus to R-CHOP chemotherapy. (exploratory)

OUTLINE: This is a multicenter, dose-escalation study of everolimus followed by a
feasability expanded-cohort study.

Patients receive everolimus orally (PO) once daily (QD) on days 1-10 or 1-14; rituximab IV,
cyclophosphamide IV, doxorubicin hydrochloride IV over 15-60 minutes, and vincristine
sulfate IV on day 1; and prednisone PO QD on days 1-5. Treatment repeats every 21 days for
up to 6 courses in the absence of disease progression or unacceptable toxicity.

Tumor biopsies are collected for laboratory studies and patients may undergo blood and
needle biopsy sample collection for correlative studies.

After completion of study treatment, patients are followed up every 3-6 months for up to 5

Inclusion Criteria


- Untreated, histological diagnosis of CD20-positive diffuse large B-cell lymphoma

- Stage II-IV (Ann Arbor Staging)

- Measurable or assessable disease defined as at least one of the following:

- A lymph node or tumor mass that is ≥ 2.0 cm in at least one dimension by CT
portion of PET/CT scan, CT scan, or MRI

- Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral
blood, liver, lungs, or bowel by lymphoma without a discrete mass would
constitute assessable, but not measurable, disease

- Diagnostic tissue slides and paraffin-embedded block must be available

- No CNS lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells


- ECOG performance status 0-2

- Absolute neutrophil count (ANC) ≥ 1,500/mm³

- Peripheral platelet count ≥ 100,000/mm³

- Hemoglobin (HgB) > 9.0 g/dL

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- For total bilirubin > 1.5 times ULN, the direct bilirubin must be normal

- Alkaline phosphatase ≤ 3 times ULN (≤ 5 times ULN if evidence of direct liver
involvement by lymphoma)

- AST ≤ 3 times ULN (≤ 5 times ULN if evidence of direct liver involvement by lymphoma)

- Creatinine ≤ ULN

- Negative serum or urine pregnancy test

- Not pregnant or nursing

- Men or women of childbearing potential must be willing to employ adequate
contraception throughout the study and for12 months after the last dose of study drug

- Willing to return to the National Central Cancer Treatment Group (NCCTG) enrolling
institution for follow-up

- Willing to provide archival tissue from the primary diagnosis (original lymphoma
lymph node tissue biopsy)

- Willing to abstain from eating grapefruit or drinking grapefruit juice for the
duration of the study

- Diabetic patients who are taking insulin or oral anti-diabetic therapy must have
HbA1c ≤ 8%, or a fasting serum glucose ≤ 110% ULN

- HIV-positive patients must have CD4 count ≥ 400/mm³

- No co-morbid systemic illnesses or other severe concurrent disease that, in the
judgment of the investigator, would make the patient inappropriate for entry into
this study or interfere significantly with the proper assessment of safety and
toxicity of the prescribed regimens

- No immunocompromised patients (other than that related to the use of corticosteroids)
including patients known to be HIV positive with a CD4 count of < 400/mm³

- No uncontrolled intercurrent illness including, but not limited to, any of the

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Severely impaired lung function

- Uncontrolled diabetes as defined by fasting serum glucose > 1.5 times ULN

- Optimal glycemic control should be achieved before starting trial therapy

- Psychiatric illness/social situations that would limit compliance with study

- Liver disease such as cirrhosis or severe hepatic impairment

- Chronic active hepatitis

- Chronic persistent hepatitis or history of hepatitis B or C

- No other active malignancy except non-melanotic skin cancer or carcinoma in situ of
the cervix

- If there is a history of prior malignancy, patients must not be receiving other
specific treatment (other than hormonal therapy) for their cancer

- No positive hepatitis B antigen (HBsAg) or hepatitis C serology (HCV) tests meeting
the following criteria:

- Hepatitis B surface antigen (HbsAg) and antibody to hepatitis B core (anti-HBc)
or hepatitis C antibody

- All patients must be screened prior to registration

- Patients who have evidence of chronic or acute infection with either hepatitis B
or C may not be treated on this protocol


- Not receiving any other investigational agent that would be considered as a treatment
for the primary neoplasm

- No planned immunization with attenuated live vaccines ≤ 7 days prior to registration
or during study period

- Close contact with those who have received attenuated live vaccines should be
avoided during treatment with everolimus

- Examples of live vaccines include intranasal influenza, measles, mumps, rubella,
oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines

- Not currently on enzyme-inducing anti-convulsants or other strong inducers of CYP3A4
(efavirenz, nevirapine, barbiturates, carbamazepine, modafinil, phenobarbital,
phenytoin, rifabutin, rifampin, pioglitazone, or St. John wort) or strong inhibitors
of CYP3A4 (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole,
voriconazole, ketoconazole, nefazodone, saquinavir, or telithromycin)

Type of Study:


Study Design:

Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD of everolimus in combination with R-CHOP

Safety Issue:


Principal Investigator

Patrick Johnston, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic



Study ID:




Start Date:

March 2012

Completion Date:

Related Keywords:

  • Lymphoma
  • contiguous stage II adult diffuse large cell lymphoma
  • noncontiguous stage II adult diffuse large cell lymphoma
  • stage III adult diffuse large cell lymphoma
  • stage IV adult diffuse large cell lymphoma
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse



Mayo Clinic Cancer Center Rochester, Minnesota  55905